In the MedTech sector, regulatory compliance is pervasive. CE marking, FDA processes, ISO 13485, MDR - companies invest heavily in documenting their processes and validating their devices. This is necessary. It is not sufficient.
What regulatory frameworks do not cover is the integrity of the people and organisations surrounding the device - clinical partners, critical suppliers, regional distributors, key international hires.
The clinical partner: an underestimated reputational risk
For a MedTech company in clinical trial or commercial deployment phase, partner hospitals, principal investigators and Key Opinion Leaders are strategic assets. Their reputation is inseparable from the credibility of the device.
Yet these partnerships are often built on personal relationships, recommendations within the medical community, or a presence at scientific conferences. No one systematically verifies the principal investigator's profile beyond their academic publications. No one cross-references a KOL's background with judicial databases or press archives to detect an undisclosed conflict of interest or past disciplinary proceeding.
In an environment under FDA oversight or CE marking, a clinical partner whose profile raises concerns can compromise the credibility of an entire study - and by extension, the regulatory dossier that relies on it.
The critical supplier: chain integrity
A Class II or III medical device depends on a supply chain whose integrity conditions both the quality of the device and the solidity of the regulatory dossier. A critical component supplier whose director has a judicial history in another jurisdiction, or whose ownership structure has changed without formal notification, creates an exposure that ISO quality audits do not detect.
The question is not only 'does this supplier deliver on time and to specification?' - it is 'who is this supplier, who is behind it, and is its profile compatible with what our regulatory dossier and institutional partners expect of us?'
International hires under time pressure
Growing MedTech companies recruit senior profiles in markets they know little: a medical director for Germany, a regulatory affairs manager for the US, a commercial director for the Middle East. These hires often happen under time pressure, via local recommendations, with verification processes insufficient for such sensitive environments.
A candidate whose past affiliations create a conflict of interest with a competitor or local regulator. A regulatory manager whose declared background does not exactly match available sources. These elements deserve to be independently verified before the relationship is engaged.
What we do for MedTech companies
At YMV & Co., we conduct independent verifications on clinical partners, strategic suppliers and key hires for MedTech companies. Our OSINT approach covers regulatory and judicial footprint, affiliations and potential conflicts of interest, consistency of declared backgrounds and exposure to sensitive databases. The deliverable is a Go / No-Go / Monitor report, structured to remain defensible before regulatory authorities and institutional partners.